Rapid Micro Biosystems (RPID) director adds shares plus Series A and B warrants
Rhea-AI Filing Summary
Rapid Micro Biosystems director Inese Lowenstein increased her stake through a combined share purchase and warrant grant. On May 29, 2026, she acquired 12,787 shares of Class A Common Stock at $1.955 per share in a registered direct offering, together with Series A and Series B Warrants to purchase 12,787 shares each. The Series A Warrant has a $1.955 exercise price and expires on May 29, 2027, while the Series B Warrant has a $2.34 exercise price and expires on May 29, 2031. After this transaction, she directly holds 70,687 Class A shares. The warrants are subject to a 4.99% beneficial ownership cap that restricts exercises that would push her above that ownership level.
Positive
- None.
Negative
- None.
Insider Trade Summary
3 transactions reported
Mixed
3 txns
Insider
LOWENSTEIN INESE
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Series A Warrant (right to buy) | 12,787 | $0.00 | -- |
| Grant/Award | Series B Warrant (right to buy) | 12,787 | $0.00 | -- |
| Grant/Award | Class A Common Stock | 12,787 | $1.955 | $25K |
Holdings After Transaction:
Series A Warrant (right to buy) — 12,787 shares (Direct);
Series B Warrant (right to buy) — 12,787 shares (Direct);
Class A Common Stock — 70,687 shares (Direct)
Footnotes (1)
- On May 29, 2026, the Reporting Person purchased, in a registered direct offering, 12,787 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each share of Issuer Class A Common Stock and accompanying Series A and Series B Warrant was $1.955. The issuance of such securities was approved by the Issuer's compensation committee of the board of directors in accordance with Rule 16(b)-3 of the Securities Exchange Act of 1934, as amended. The Series A and Series B Warrants cannot be exercised for shares of the Issuer's Class A Common Stock if, as a result of such exercise, the holder, together with its affiliates and any other persons whose beneficial ownership would be aggregated for purposes of Section 13(d) of the Act, would beneficially own more than 4.99% of the total number of shares of the Issuer's Class A Common Stock then outstanding immediately following such exercise.
Key Figures
Shares acquired: 12,787 shares
Purchase price: $1.955 per share
Post-transaction holdings: 70,687 shares
+5 more
8 metrics
Shares acquired
12,787 shares
Class A Common Stock acquired on May 29, 2026 at $1.955
Purchase price
$1.955 per share
Price per share for Class A stock plus accompanying warrants
Post-transaction holdings
70,687 shares
Total Class A Common Stock directly held after the transaction
Series A Warrant size
12,787 shares
Underlying Class A shares for Series A Warrant
Series A exercise price
$1.955 per share
Exercise price for Series A Warrant
Series A expiration
May 29, 2027
Expiration date of Series A Warrant
Series B exercise price
$2.34 per share
Exercise price for Series B Warrant
Series B expiration
May 29, 2031
Expiration date of Series B Warrant
Key Terms
registered direct offering, Series A Warrant, Series B Warrant, Rule 16(b)-3, +2 more
6 terms
registered direct offering financial
"the Reporting Person purchased, in a registered direct offering, 12,787 shares"
A registered direct offering is a way for a company to sell new shares of its stock directly to select investors with regulatory approval. This method allows the company to raise funds quickly and efficiently without needing a public auction, similar to offering exclusive access to a limited number of buyers. For investors, it often provides an opportunity to purchase shares at a favorable price, while giving the company immediate access to capital.
Series A Warrant financial
"an accompanying Series A Warrant to purchase 12,787 shares"
A Series A warrant is a contract issued alongside a company’s early funding round that gives the holder the right to buy a set number of shares later at a fixed price. Think of it like a coupon that lets an investor purchase stock at today’s agreed price even if the company’s value rises; it can boost potential upside for the warrant holder and create dilution for existing shareholders, so investors watch them when assessing ownership and future share value.
Series B Warrant financial
"an accompanying Series B Warrant to purchase 12,787 shares"
A Series B warrant is a tradable right issued alongside a Series B funding round that lets its holder buy a specified number of company shares at a fixed price for a set period. It matters to investors because exercising the warrant increases the total shares outstanding (dilution) and can be a cheap way to gain ownership if the company’s value rises — think of it like a coupon to buy stock later at today’s price.
Rule 16(b)-3 regulatory
"approved by the Issuer's compensation committee ... in accordance with Rule 16(b)-3"
Section 13(d) regulatory
"beneficial ownership would be aggregated for purposes of Section 13(d) of the Act"
beneficially own more than 4.99% financial
"would beneficially own more than 4.99% of the total number of shares"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did Inese Lowenstein acquire in the latest Form 4 for RPID?
Inese Lowenstein acquired 12,787 shares of Rapid Micro Biosystems Class A stock and matching Series A and Series B Warrants for 12,787 shares each, all tied to a $1.955 per-share purchase in a registered direct offering approved by the compensation committee.
What are the key terms of the RPID Series A and Series B Warrants?
The Series A Warrant covers 12,787 shares at a $1.955 exercise price and expires May 29, 2027. The Series B Warrant also covers 12,787 shares, with a $2.34 exercise price and a longer expiration date of May 29, 2031.
Is there an ownership cap on exercising the RPID warrants?
Yes. The Series A and Series B Warrants cannot be exercised if doing so would cause the holder and certain related parties to beneficially own more than 4.99% of Rapid Micro Biosystems Class A shares outstanding immediately after the exercise.